Raptor Pharmaceuticals Corp. (RPC), formerly TorreyPines Therapeutics, Inc., is an early development-stage Company. The Company�s product portfolio includes both candidates from its drug targeting platforms and in-licensed and acquired product candidates. As of August 31, 2010, its pipeline includes three clinical development programs. It also has three other clinical-stage product candidates, for which it is seeking business development partners, and it has four preclinical product candidates it is developing, three of which are based upon its drug-targeting platforms. As of August 31, 2010, the Company had no revenues. On September 29, 2009, the Company and its wholly owned subsidiary, ECP Acquisition, Inc., completed a reverse merger, business combination with RPC, pursuant to which RPC became its wholly owned subsidiary.